BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kythera Biopharmaceuticals Prices IPO


9/28/2012 8:40:09 AM

Kythera Biopharmaceuticals Inc. has set a pricing range for its planned initial public offering of 4 million shares at $14 to $16 per share.

The Calabasas-based company, which is in clinical stages for developing a drug to treat chin fat, is seeking to list on the Nasdaq Global Market under the ticker symbol KYTH.

The company filed a registration statement with the Securities and Exchange Commission for the IPO in May. It said J.P. Morgan Securities LLC and Goldman, Sachs & Co. will act as joint book-running managers for the offering. Leerink Swann LLC will act as lead co-manager and Lazard Capital Markets LLC will act as co-manager.

Kythera’s is developing ATX-101, is a potential injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable “double chin.” In August 2010, pharmaceutical giant Bayer AG signed a licensing and collaboration development agreement with Kythera, giving it development and commercialization rights to ATX-101 outside of the United States and Canada.

Kythera’s investors include Versant Ventures, Arch Venture Partners, Prospect Venture Partners and Jafco.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES